| PD-1/PD-L1抑制剂联合其他免疫检查点抑制剂治疗三阴性乳腺癌的研究进展#br# |
| |
| 引用本文： | 崔语恒,赵少荣,刘晶晶,张瑾. PD-1/PD-L1抑制剂联合其他免疫检查点抑制剂治疗三阴性乳腺癌的研究进展#br#[J]. 天津医药, 2020, 48(12): 1230-1235. DOI: 10.11958/20200705 |
| |
| 作者姓名： | 崔语恒 赵少荣 刘晶晶 张瑾 |
| |
| 作者单位： | 天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心（邮编300060） |
| |
| 基金项目： | 国家自然科学基金面上项目（81672623） |
| |
| 摘 要： | 三阴性乳腺癌（TNBC）具有全身转移率高、对常规治疗不敏感以及容易产生耐药性等特点，导致患者的预后较差。随着对机体免疫系统抗肿瘤机制及TNBC免疫特点的不断探究，以程序性细胞死亡蛋白1（PD-1）和程序性死亡蛋白配体1（PD-L1）为代表的免疫检查点抑制剂为TNBC提供了新的治疗方案，但PD-1/PD-L1抑制剂单药治疗的效果不甚理想。本文就PD-1/PD-L1抑制剂联合其他具有不同机制的免疫检查点抑制剂在TNBC患者中的应用进行综述。
|
| 关 键 词： | 三阴性乳腺癌 程序性细胞死亡受体1 程序性细胞死亡蛋白1 免疫检查点抑制剂 PD-1/PD-L1抑制剂 |
| 收稿时间： | 2020-03-29 |
| 修稿时间： | 2020-08-21 |
Research progress of PD-1/PD-L1 inhibitors combined with other immune checkpoint inhibitors in the treatment of triple negative breast cancer |
| |
| CUI Yu-heng,ZHAO Shao-rong,LIU Jing-jing,ZHANG Jin. Research progress of PD-1/PD-L1 inhibitors combined with other immune checkpoint inhibitors in the treatment of triple negative breast cancer[J]. Tianjin Medical Journal, 2020, 48(12): 1230-1235. DOI: 10.11958/20200705 |
| |
| Authors: | CUI Yu-heng ZHAO Shao-rong LIU Jing-jing ZHANG Jin |
| |
| Affiliation: | Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China |
| |
| Abstract: | The poor prognosis of patients with triple-negative breast cancer (TNBC) is related to its high systemic metastasis rate, insensitivity to conventional treatment and easy development of drug resistance. With the continuous exploration of anti-tumor mechanism of immune system and immune characteristics of TNBC, immune checkpoint inhibitors represented by programmed cell death protein 1 (PD-1) and programmed death protein ligand 1 (PD-L1) provide new treatment options for TNBC. However, the effect of PD-1/PD-L1 inhibitor monotherapy is not ideal. Therefore, this article aims to explore the application of PD-1/PD-L1 inhibitors combined with other immune checkpoint inhibitors with different mechanisms in the treatment of TNBC patients. |
| |
| Keywords: | triple negative breast neoplasms programmed cell death 1 receptor programmed cell death protein 1 immune checkpoint inhibitors PD-1/PD-L1 inhibitor |
|
| 点击此处可从《天津医药》浏览原始摘要信息 |
|
点击此处可从《天津医药》下载全文 |
